MedTrace Logo

NWRD09 for Persistent Cervical HPV16 Infection

NCT07710703 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-07-17

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo controlled study to determine the efficacy and safety of NWRD09 in adult women with persistent cervical HPV16 infection.

Conditions

  • Persistent Cervical HPV16 Infection

Interventions

BIOLOGICAL

NWRD09/ Placebo administered by IM injection

NWRD09/ Placebo

Sponsors & Collaborators

  • Newish Biotech (Wuxi) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-10
Primary Completion
2026-11-30
Completion
2027-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07710703 on ClinicalTrials.gov